Synvista Therapeutics, Inc. (SYNI)

Overview

Synvista Therapeutics, Inc. is a forward-thinking biopharmaceutical company engaged in the development of innovative diagnostic tests and therapeutic drugs targeting diabetic patients who are at elevated risk for cardiovascular diseases. Originating in 1986 and initially known as Alteon, Inc., the company has established its headquarters in Montvale, New Jersey. Synvista Therapeutics is committed to improving patient outcomes through its focused research on cardiovascular complications associated with diabetes.

Products and Services

• ALT-2074 (Glutathione Peroxidase Mimetic)

  This compound is at the forefront of Synvista’s innovative research, currently in Phase II clinical trials. ALT-2074 is specifically designed for diabetic patients who possess the Hp2-2 genotype, targeting oxidative stress pathways that are critically involved in the progression of cardiovascular disease in this patient population.

• Alagebrium Chloride (Alagebrium)

  Alagebrium, another hallmark product in development by Synvista Therapeutics, is an Advanced Glycation End-product Crosslink Breaker. It is under Phase II clinical trials, aimed at treating conditions such as diastolic heart failure and diabetic nephropathy. Alagebrium's mechanism of action focuses on breaking the chemical bonds formed by advanced glycation end-products, which are often elevated in diabetic patients and contribute to the stiffening of the heart muscle and kidney damage.

• Diagnostic Test for Cardiovascular Disease Risk in Diabetic Patients

  In addition to therapeutic interventions, Synvista Therapeutics is diligently working on a diagnostic test intended to identify diabetic patients who are at high risk for developing cardiovascular disease. This diagnostic tool aims to enable early intervention strategies, thereby potentially reducing the morbidity and mortality associated with diabetic cardiovascular complications.